Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937350 · ClinicalTrials.gov registry record · Phase 1
Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT02937350: Completed Phase 1 study, sponsored by University of Washington.
NCT02937350 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02937350, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.
Primary Outcome
Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.
Interventions
- DRUG D6-25-hydroxyvitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 1 |
What the finished NCT02937350 record still lists
NCT02937350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 1 intervention - of which D6-25-hydroxyvitamin D3 is the first listed.
NCT02937350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02937350 about?
NCT02937350 is a clinical study titled "Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease". The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.
What is the current status of trial NCT02937350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2017-03-01. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT02937350?
The interventions under investigation include: D6-25-hydroxyvitamin D3 (DRUG).
Who is sponsoring clinical trial NCT02937350?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02937350's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI